Bristol-Myers Squibb Company with ticker code (BMY) now have 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $83.34 and $38.89 with the average target price sitting at $57.83. Now with the previous closing price of $51.86 this would imply there is now a potential upside of 11.5%. The 50 day MA is $52.53 and the 200 day moving average is $61.58. The market cap for the company is 105.52B. The stock price is currently at: $51.47 USD
The potential market cap would be $117,670,295,943 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 13.06, revenue per share of $21.51 and a 5.59% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
